ATE440097T1 - Substituierte hydantoine zur krebsbehandlung - Google Patents
Substituierte hydantoine zur krebsbehandlungInfo
- Publication number
- ATE440097T1 ATE440097T1 AT05784418T AT05784418T ATE440097T1 AT E440097 T1 ATE440097 T1 AT E440097T1 AT 05784418 T AT05784418 T AT 05784418T AT 05784418 T AT05784418 T AT 05784418T AT E440097 T1 ATE440097 T1 AT E440097T1
- Authority
- AT
- Austria
- Prior art keywords
- cancer treatment
- substituted hydantoins
- hydantoins
- substituted
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61065504P | 2004-09-17 | 2004-09-17 | |
| PCT/EP2005/009926 WO2006029862A1 (en) | 2004-09-17 | 2005-09-15 | Substituted hydantoins for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE440097T1 true ATE440097T1 (de) | 2009-09-15 |
Family
ID=35447646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05784418T ATE440097T1 (de) | 2004-09-17 | 2005-09-15 | Substituierte hydantoine zur krebsbehandlung |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7371869B2 (de) |
| EP (1) | EP1791837B1 (de) |
| JP (1) | JP4685873B2 (de) |
| KR (1) | KR100869681B1 (de) |
| CN (1) | CN101023079B (de) |
| AR (1) | AR051290A1 (de) |
| AT (1) | ATE440097T1 (de) |
| AU (1) | AU2005284293B2 (de) |
| BR (1) | BRPI0515371A (de) |
| CA (1) | CA2579130A1 (de) |
| DE (1) | DE602005016127D1 (de) |
| ES (1) | ES2329264T3 (de) |
| MX (1) | MX2007003166A (de) |
| RU (1) | RU2393156C2 (de) |
| TW (1) | TW200621766A (de) |
| WO (1) | WO2006029862A1 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612212B2 (en) | 2006-02-22 | 2009-11-03 | Hoffmann-La Roche Inc. | Substituted hydantoins |
| JP2010526848A (ja) * | 2007-05-11 | 2010-08-05 | エフ.ホフマン−ラ ロシュ アーゲー | 難溶性薬物用の医薬組成物 |
| EP2188276B1 (de) | 2007-08-16 | 2012-03-28 | F. Hoffmann-La Roche AG | Substituierte hydantoine |
| CN101896469A (zh) * | 2007-12-20 | 2010-11-24 | 霍夫曼-拉罗奇有限公司 | 作为mek激酶抑制剂的取代的乙内酰脲类化合物 |
| EP2346818B1 (de) | 2008-11-10 | 2012-12-05 | Bayer Intellectual Property GmbH | Substituierte sulfonamidophenoxybenzamide |
| EP2370568B1 (de) | 2008-12-10 | 2017-07-19 | Dana-Farber Cancer Institute, Inc. | Mek mutanten mit resistenz gegen mek inhibitoren |
| CA2777430A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Pharma Aktiengesellschaft | Substituted benzosulphonamides |
| US8962606B2 (en) | 2009-10-21 | 2015-02-24 | Bayer Intellectual Property Gmbh | Substituted benzosulphonamides |
| CN102574782B (zh) | 2009-10-21 | 2014-10-08 | 拜耳知识产权有限责任公司 | 取代的卤代苯氧基苯甲酰胺衍生物 |
| US10632106B2 (en) | 2009-11-02 | 2020-04-28 | Ariagen, Inc. | Methods of cancer treatment with 2-(1′H-Indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester |
| ES2791684T3 (es) | 2009-11-02 | 2020-11-05 | Ariagen Inc | ITE para la intervención y erradicación del cáncer |
| CA2789696C (en) | 2010-02-25 | 2017-11-07 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
| EP2545187B1 (de) | 2010-03-09 | 2018-09-05 | Dana-Farber Cancer Institute, Inc. | Verfahren zur diagnose und behandlung von krebs bei patienten mit resistenz bzw. entwicklung einer resistenz gegenüber einer ersten krebstherapie |
| WO2012055953A1 (en) | 2010-10-29 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Substituted phenoxypyridines |
| KR101472175B1 (ko) | 2012-02-17 | 2014-12-15 | 중앙대학교 산학협력단 | 신규한 2-아미노티아졸 유도체 및 이를 유효성분으로 포함하는 항암용 조성물 |
| WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| KR102282187B1 (ko) | 2014-09-12 | 2021-07-26 | 아리아젠, 인크. | 2-(1'h-인돌-3'-카르보닐)-티아졸-4-카르복실산 메틸 에스테르 및 그의 구조 유사체의 효율적이고 확장 가능한 합성 |
| RU2605091C2 (ru) * | 2015-05-12 | 2016-12-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Казанский государственный медицинский университет" Министерства здравоохранения и социального развития" | 2-амино-1-арил-5-(3,3-диметил-2-оксобутилиден)-4-оксо-n-(тиазол-5-ил)-4,5-дигидро-1н-пиррол-3-карбоксамиды, проявляющие противоопухолевую и антирадикальную активность, способ их получения и фармацевтическая композиция на их основе |
| CN113480530A (zh) | 2016-12-26 | 2021-10-08 | 阿里根公司 | 芳香烃受体调节剂 |
| SI3612531T1 (sl) | 2017-04-18 | 2022-11-30 | Shanghai Fochon Pharmaceutical Co., Ltd. | Sredstva, ki sprožajo apoptozo |
| WO2019099977A2 (en) | 2017-11-20 | 2019-05-23 | Ariagen, Inc. | Indole compounds and their use |
| US10555558B2 (en) | 2017-12-29 | 2020-02-11 | Rai Strategic Holdings, Inc. | Aerosol delivery device providing flavor control |
| TW202104218A (zh) | 2019-04-15 | 2021-02-01 | 美商雅里俊公司 | 對掌性吲哚化合物及其用途 |
| WO2021027722A1 (zh) * | 2019-08-09 | 2021-02-18 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2229515T3 (es) | 1997-07-01 | 2005-04-16 | Warner-Lambert Company Llc | Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek. |
| KR19990012061A (ko) | 1997-07-26 | 1999-02-25 | 성재갑 | 파네실 전이효소 저해제로 유용한 하이덴토인 유도체 |
| ATE304011T1 (de) | 2000-05-03 | 2005-09-15 | Hoffmann La Roche | Hydantoin-enthaltende glucokinase aktivatoren |
| JP2004534857A (ja) * | 2001-07-19 | 2004-11-18 | フアルマシア・イタリア・エツセ・ピー・アー | フェニルアセトアミド−チアゾール誘導体、それらの製造のための方法及び抗癌剤としてのそれらの使用 |
| MX2007001846A (es) * | 2004-08-17 | 2007-03-28 | Hoffmann La Roche | Hidantoinas sustituidas. |
-
2005
- 2005-09-13 TW TW094131490A patent/TW200621766A/zh unknown
- 2005-09-14 US US11/225,950 patent/US7371869B2/en not_active Expired - Fee Related
- 2005-09-15 AU AU2005284293A patent/AU2005284293B2/en not_active Ceased
- 2005-09-15 KR KR1020077006190A patent/KR100869681B1/ko not_active Expired - Fee Related
- 2005-09-15 DE DE602005016127T patent/DE602005016127D1/de not_active Expired - Lifetime
- 2005-09-15 JP JP2007531676A patent/JP4685873B2/ja not_active Expired - Fee Related
- 2005-09-15 WO PCT/EP2005/009926 patent/WO2006029862A1/en not_active Ceased
- 2005-09-15 AT AT05784418T patent/ATE440097T1/de not_active IP Right Cessation
- 2005-09-15 CA CA002579130A patent/CA2579130A1/en not_active Abandoned
- 2005-09-15 EP EP05784418A patent/EP1791837B1/de not_active Expired - Lifetime
- 2005-09-15 CN CN2005800310488A patent/CN101023079B/zh not_active Expired - Fee Related
- 2005-09-15 MX MX2007003166A patent/MX2007003166A/es active IP Right Grant
- 2005-09-15 ES ES05784418T patent/ES2329264T3/es not_active Expired - Lifetime
- 2005-09-15 BR BRPI0515371-9A patent/BRPI0515371A/pt not_active IP Right Cessation
- 2005-09-15 AR ARP050103857A patent/AR051290A1/es unknown
- 2005-09-15 RU RU2007114125/04A patent/RU2393156C2/ru not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008513397A (ja) | 2008-05-01 |
| AR051290A1 (es) | 2007-01-03 |
| CN101023079B (zh) | 2010-05-05 |
| TW200621766A (en) | 2006-07-01 |
| AU2005284293B2 (en) | 2011-10-06 |
| ES2329264T3 (es) | 2009-11-24 |
| EP1791837B1 (de) | 2009-08-19 |
| CA2579130A1 (en) | 2006-03-23 |
| KR100869681B1 (ko) | 2008-11-21 |
| KR20070043895A (ko) | 2007-04-25 |
| MX2007003166A (es) | 2007-05-15 |
| RU2007114125A (ru) | 2008-10-27 |
| US7371869B2 (en) | 2008-05-13 |
| US20060063814A1 (en) | 2006-03-23 |
| CN101023079A (zh) | 2007-08-22 |
| WO2006029862A1 (en) | 2006-03-23 |
| BRPI0515371A (pt) | 2008-07-22 |
| JP4685873B2 (ja) | 2011-05-18 |
| DE602005016127D1 (de) | 2009-10-01 |
| AU2005284293A1 (en) | 2006-03-23 |
| RU2393156C2 (ru) | 2010-06-27 |
| EP1791837A1 (de) | 2007-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602005016127D1 (de) | Substituierte hydantoine zur krebsbehandlung | |
| IL197217B (en) | Novel anti-cd38 antibodies for the treatment of cancer | |
| DE602008005894D1 (de) | Kondensierte imidazole zur krebsbehandlung | |
| DE602005027052D1 (de) | Endoskopbehandlungssystem | |
| CY2200156T2 (el) | Επεξεργασια λυματων | |
| NO20070251A (no) | Brønnbehandling | |
| NO20070297A (no) | Brønnbehandling | |
| BRPI0810206A2 (pt) | Método de tratar câncer | |
| ATE435271T1 (de) | Zusammensetzungen zur wäschebehandlung | |
| ATE430187T1 (de) | Zusammensetzungen zur wäschebehandlung | |
| PT1937244T (pt) | Tratamento do cancro com agonistas específicos de rxr | |
| EP1753506A4 (de) | Leitungsloser implantierbarer kardioverter-defribrillator | |
| EP1967209A4 (de) | Therapeutisches mittel gegen prostatakrebs | |
| EP1718193A4 (de) | Endoskop-anordnung | |
| HUE054495T2 (hu) | Rák kezelésére szolgáló készítmény | |
| IL188430A0 (en) | Treatment of tumors | |
| DE602004021940D1 (de) | Endoskopsystem | |
| ATE404556T1 (de) | Substituierte hydantoine | |
| IL182993A0 (en) | Treatment of mastitis | |
| EP1949895A4 (de) | Iontophorese-zubereitung | |
| EP1830847A4 (de) | Krebsbehandlung | |
| DK1630309T3 (da) | Afløb | |
| DE602005021084D1 (de) | ENDOSKOPisches BEHANDLUNGSSYSTEM | |
| EP1765735A4 (de) | Schlammbehandlungsverfahren | |
| EP1789064A4 (de) | Verbesserte krebsbehandlung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |